

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2019/2020 influenza season**

as of January 9, 2020, June 30, 2020

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	0	12 <sup>a</sup> (2.0%)	12 <sup>a</sup> (2.0%)	0	0	10 (100%)	0	0	0	0	0	5 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	177	601	601	125	125	10	17	10	10	10	10	5	2	8	8	8	8
<b>Number of viruses reported</b>	1,396						54						39				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patients without treatment 8